Boswellic Acids in Multiple Sclerosis
SAFETY, TOLERABILITY AND MECHANISM OF ACTION OF BOSWELLIC ACIDS (BA) IN MULTIPLE SCLEROSIS (MS) AND CLINICALLY ISOLATED SYNDROME (CIS):
What it found
No results found
We found no results in the registry or in papers.
What was tested
Treatment tested
- BOSWELAN
What it measured
Main measures
Number and volume of total Gd-enhancing lesions
MRI lesions
Other measures (1)
• Number of persisting Gd-enhancing lesions
MRI lesions
Who could take part
Relapsing MS
Show the full criteria
Inclusion criteria
Inclusion: - Between the ages of 18 and 65 years, inclusive Exclusion: - ALT (SGPT) or AST (SGOT) > three times the upper limit of normal
Exclusion criteria
Not separately supplied in the registry.
As registered. Criteria can change, so ask the trial team or your neurologist.
About this trial
In the sponsor's words
To determine the safety and tolerability of BOSWELAN in subjects with multiple sclerosis or clinically isolated syndrome
Loading reviews and guidelines…
History
Started
Oct 2010
Assembled by software from public sources.